Literature DB >> 19171675

Dual mechanisms of CYP3A protein regulation by proinflammatory cytokine stimulation in primary hepatocyte cultures.

Choon-Myung Lee1, Jan Pohl, Edward T Morgan.   

Abstract

Whereas many cytochrome P450 enzymes are transcriptionally suppressed by inflammatory stimuli, down-regulation of CYP2B protein by the inflammatory cytokine interleukin (IL)-1beta is nitric oxide (NO)-dependent and occurs via polyubiquitination and proteasomal degradation. Here, we used iTRAQ proteomic analysis to search for other proteins that are potentially down-regulated by cellular NO in cultured rat hepatocytes, and we identified CYP3A1 as one such protein. Therefore, we examined whether CYP3A proteins, like CYP2B, undergo NO- and proteasome-dependent degradation in response to cytokine treatment of rat hepatocytes. In cultured rat hepatocytes treated with phenobarbital, IL-1beta stimulation failed to down-regulate CYP3A1 mRNA within 24 h of treatment, whereas CYP3A protein was down-regulated to 40% of control within 6 h, showing the post-transcriptional down-regulation of CYP3A1 protein. The down-regulation of CYP3A after 9 h of stimulation by IL-1beta was attenuated by inhibitors of NO synthase (NOS) and of the proteasome, showing NO- and proteasome-dependent down-regulation at earlier time points. However, the down-regulation of CYP3A evoked by IL-1beta measured 24 h after stimulation was not affected by the inhibition of NOS or by proteasomal inhibitors, showing that CYP3A1 down-regulation at later time points is NO- and proteasome-independent. IL-6, which did not evoke NO production nor affect CYP3A1 mRNA within 24 h, produced a delayed proteasome-independent down-regulation as well. Taken together, these observations show a novel dual mode of post-transcriptional CYP3A down-regulation by cytokines: NO- and proteasome-dependent at earlier time points and NO- and proteasome-independent at later times.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19171675      PMCID: PMC2680532          DOI: 10.1124/dmd.108.026187

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  30 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Role of nitric oxide in down-regulation of CYP2B1 protein, but not RNA, in primary cultures of rat hepatocytes.

Authors:  L Ferrari; N Peng; J R Halpert; E T Morgan
Journal:  Mol Pharmacol       Date:  2001-07       Impact factor: 4.436

3.  Selective induction of cytochrome P450 3A1 by dexamethasone in cultured rat hepatocytes: analysis with a novel reverse transcriptase-polymerase chain reaction assay section sign.

Authors:  P A Hoen; J N Commandeur; N P Vermeulen; T J Van Berkel; M K Bijsterbosch
Journal:  Biochem Pharmacol       Date:  2000-11-15       Impact factor: 5.858

4.  Hepatic expression of multiple acute phase proteins and down-regulation of nuclear receptors after acute endotoxin exposure.

Authors:  Che Fang; Seokjoo Yoon; Niclas Tindberg; Harri A Järveläinen; Kai O Lindros; Magnus Ingelman-Sundberg
Journal:  Biochem Pharmacol       Date:  2004-04-01       Impact factor: 5.858

5.  Suppression of cytochrome P450 3A protein levels by proteasome inhibitors.

Authors:  Richard C Zangar; Thomas A Kocarek; Shang Shen; Nikki Bollinger; Michael S Dahn; Donna W Lee
Journal:  J Pharmacol Exp Ther       Date:  2003-03-06       Impact factor: 4.030

Review 6.  Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts.

Authors:  Xinxin Ding; Laurence S Kaminsky
Journal:  Annu Rev Pharmacol Toxicol       Date:  2002-01-10       Impact factor: 13.820

7.  Roles of nitric oxide in inflammatory downregulation of human cytochromes P450.

Authors:  Alison E Aitken; Choon-Myung Lee; Edward T Morgan
Journal:  Free Radic Biol Med       Date:  2007-12-23       Impact factor: 7.376

8.  S-nitrosylation of IRP2 regulates its stability via the ubiquitin-proteasome pathway.

Authors:  Sangwon Kim; Simon S Wing; Prem Ponka
Journal:  Mol Cell Biol       Date:  2004-01       Impact factor: 4.272

Review 9.  The role of cytochrome P450 in cytotoxic bioactivation: future therapeutic directions.

Authors:  P H Rooney; C Telfer; M C E McFadyen; W T Melvin; G I Murray
Journal:  Curr Cancer Drug Targets       Date:  2004-05       Impact factor: 3.428

10.  Nitric oxide induces degradation of the neutral ceramidase in rat renal mesangial cells and is counterregulated by protein kinase C.

Authors:  Rochus Franzen; Doriano Fabbro; Armaz Aschrafi; Josef Pfeilschifter; Andrea Huwiler
Journal:  J Biol Chem       Date:  2002-09-30       Impact factor: 5.157

View more
  22 in total

1.  Nitric oxide-regulated proteolysis of human CYP2B6 via the ubiquitin-proteasome system.

Authors:  Choon-Myung Lee; Shweta Tripathi; Edward T Morgan
Journal:  Free Radic Biol Med       Date:  2017-04-17       Impact factor: 7.376

Review 2.  Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.

Authors:  Miroslav Dostalek; Iain Gardner; Brian M Gurbaxani; Rachel H Rose; Manoranjenni Chetty
Journal:  Clin Pharmacokinet       Date:  2013-02       Impact factor: 6.447

3.  Dexamethasone transcriptionally increases the expression of the pregnane X receptor and synergistically enhances pyrethroid esfenvalerate in the induction of cytochrome P450 3A23.

Authors:  Deshi Shi; Dongfang Yang; Bingfang Yan
Journal:  Biochem Pharmacol       Date:  2010-07-01       Impact factor: 5.858

4.  Sources of Interindividual Variability.

Authors:  Yvonne S Lin; Kenneth E Thummel; Brice D Thompson; Rheem A Totah; Christi W Cho
Journal:  Methods Mol Biol       Date:  2021

5.  Regulation of cytochrome P450 enzyme activity and expression by nitric oxide in the context of inflammatory disease.

Authors:  Edward T Morgan; Cene Skubic; Choon-Myung Lee; Kaja Blagotinšek Cokan; Damjana Rozman
Journal:  Drug Metab Rev       Date:  2020-09-08       Impact factor: 4.518

6.  Nitric oxide stimulates cellular degradation of human CYP51A1, the highly conserved lanosterol 14α-demethylase.

Authors:  Ji Won Park; Aria Byrd; Choon-Myung Lee; Edward T Morgan
Journal:  Biochem J       Date:  2017-09-14       Impact factor: 3.857

7.  Physiologically-based pharmacokinetic modelling to predict oprozomib CYP3A drug-drug interaction potential in patients with advanced malignancies.

Authors:  Ying Ou; Yang Xu; Lia Gore; R Donald Harvey; Alain Mita; Kyriakos P Papadopoulos; Zhengping Wang; Richard E Cutler; Dawn E Pinchasik; Apostolia M Tsimberidou
Journal:  Br J Clin Pharmacol       Date:  2018-12-25       Impact factor: 4.335

8.  Estrogen modulates hepatic gene expression and survival of rainbow trout infected with pathogenic bacteria Yersinia ruckeri.

Authors:  Michael Wenger; Aleksei Krasnov; Stanko Skugor; Elinor Goldschmidt-Clermont; Ursula Sattler; Sergey Afanasyev; Helmut Segner
Journal:  Mar Biotechnol (NY)       Date:  2012-07-24       Impact factor: 3.619

9.  Impact of interleukin-10 gene polymorphisms on tacrolimus dosing requirements in Chinese liver transplant patients during the early posttransplantation period.

Authors:  Xiaoqing Zhang; Zhaowen Wang; Junwei Fan; Gaolin Liu; Zhihai Peng
Journal:  Eur J Clin Pharmacol       Date:  2011-02-26       Impact factor: 2.953

10.  Association between interleukin-18 promoter variants and tacrolimus pharmacokinetics in Chinese renal transplant patients.

Authors:  Jiazhen Xing; Xiaoqing Zhang; Junwei Fan; Bin Shen; Tongyi Men; Jianning Wang
Journal:  Eur J Clin Pharmacol       Date:  2014-12-10       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.